Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma

Cutaneous T-cell lymphoma (CTCL) poses unique treatment challenges, given its range of presentations and numerous systemic therapy options. These options often lack comparative evidence or are characterized by low response rates and short remission duration in relapsed/refractory disease. The approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ollila, Thomas A, Sahin, Ilyas, Olszewski, Adam J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369856/
https://www.ncbi.nlm.nih.gov/pubmed/30799938
http://dx.doi.org/10.2147/OTT.S165615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369856/
https://www.ncbi.nlm.nih.gov/pubmed/30799938
http://dx.doi.org/10.2147/OTT.S165615

Ejemplares similares